EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

VRK1 Is a Novel Therapeutic Target for Small Cell Neuroendocrine Carcinoma of the Cervix

Mariya Kobayashi iD, Satoshi Nakagawa iD, Yusuke Ishii, Yuji Kamei, Mizuki Kanda, Tatsuo Masuda, Mamoru Kakuda, Kosuke Hiramatsu iD, Tadashi Iwamiya, Tomomi Egawa-Takata iD, Shinya Matsuzaki, Hiroyuki Uematsu und 5 weitere

Cancer Science · 2026

DOI: 10.1111/cas.70211 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Mariya Kobayashi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Osaka, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Uterine Cervical Neoplasms, Carcinoma, Small Cell, Protein Serine-Threonine Kinases. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Osaka Prefecture Subsidy for the Promotion of the Medical Career Development Support Program for 2022, 2023, and 2024.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small cell neuroendocrine carcinoma of the cervix (SCNEC) is classified as a high‐grade neuroendocrine carcinoma with a worse prognosis than other major histological types of cervical cancer. Identifying novel therapeutic targets based on its molecular characteristics is highly desirable but challenging due to the rarity of SCNEC and the resulting lack of research resources. In this study, we identified vaccinia‐related kinase 1 (VRK1) as a potential therapeutic target for SCNEC. VRK1 was prioritized based on our previously reported proteomic analysis of patient‐derived organoids. Immunohistochemistry of patient samples consistently revealed high VRK1 expression in SCNEC, as opposed to its variable expression in other cervical carcinomas. Although VRK1 knockdown in SCNEC had only a limited effect on cell proliferation in two‐dimensional cultures, it significantly suppressed cell proliferation in three‐dimensional cultures and inhibited xenograft tumor growth in vivo. Gene set enrichment analysis of RNA‐sequencing data from mouse xenograft models demonstrated that VRK1 is associated with mitochondrial‐related pathways. Furthermore, under oxidative stress conditions, VRK1 knockdown resulted in a reduction of mitochondrial membrane potential, an indicator of mitochondrial integrity, and decreased expression of cytochrome c oxidase subunit IV (COX IV), a nuclear‐encoded subunit of cytochrome c oxidase, the terminal enzyme complex of the mitochondrial respiratory chain. These findings suggest that VRK1 knockdown indirectly impaired mitochondrial function. Collectively, these anti‐tumor effects highlight VRK1 as a promising therapeutic target for SCNEC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineUterine Cervical NeoplasmsCarcinoma, Small CellProtein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsHumansFemaleAnimalsMiceCell ProliferationXenograft Model Antitumor AssaysCell Line, TumorMitochondriaElectron Transport Complex IVGene Knockdown TechniquesGene Expression Regulation, NeoplasticMembrane Potential, Mitochondrial

Stichwörter der Autor:innen

VRK1cervical cancerin vivomitochondriasmall cell neuroendocrine carcinoma

Substanzen

Protein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsVRK1 protein, humanElectron Transport Complex IV

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
  • Department of Obstetrics and Gynecology, Higashiosaka City Medical Center, Osaka, Japan.
  • Department of Clinical Bio-Resource Research and Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan.
  • Sakai City Hospital Organization, Osaka, Japan.

ORCID-Profile: Mariya Kobayashi, Satoshi Nakagawa, Kosuke Hiramatsu, Tomomi Egawa-Takata, Masahiro Inoue, Yutaka Ueda

Förderung

  • Osaka Prefecture Subsidy for the Promotion of the Medical Career Development Support Program for 2022, 2023, and 2024

Zitieren

APA

Kobayashi, M., Nakagawa, S., Ishii, Y., Kamei, Y., Kanda, M., Masuda, T., Kakuda, M., Hiramatsu, K., Iwamiya, T., Egawa-Takata, T., Matsuzaki, S., Uematsu, H., Onuma, K., Inoue, M., Ueda, Y., Kimura, T., & Kodama, M. (2026). VRK1 Is a Novel Therapeutic Target for Small Cell Neuroendocrine Carcinoma of the Cervix. Cancer Science. https://doi.org/10.1111/cas.70211

Vancouver

Kobayashi M, Nakagawa S, Ishii Y, Kamei Y, Kanda M, Masuda T, et al. VRK1 Is a Novel Therapeutic Target for Small Cell Neuroendocrine Carcinoma of the Cervix. Cancer Science. 2026. doi:10.1111/cas.70211

BibTeX
@article{Kobayashi2026,
  author = {Kobayashi, Mariya and Nakagawa, Satoshi and Ishii, Yusuke and Kamei, Yuji and Kanda, Mizuki and Masuda, Tatsuo and Kakuda, Mamoru and Hiramatsu, Kosuke and Iwamiya, Tadashi and Egawa-Takata, Tomomi and Matsuzaki, Shinya and Uematsu, Hiroyuki and Onuma, Kunishige and Inoue, Masahiro and Ueda, Yutaka and Kimura, Tadashi and Kodama, Michiko},
  title = {VRK1 Is a Novel Therapeutic Target for Small Cell Neuroendocrine Carcinoma of the Cervix},
  journal = {Cancer Science},
  year = {2026},
  doi = {10.1111/cas.70211}
}
Kostenlos starten →